Becton Dickinson Cash Flow from Investing Activities 2010-2023 | BDX
Becton Dickinson annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Becton Dickinson cash flow from investing activities for the quarter ending December 31, 2023 was $-0.233B, a 19.93% decline year-over-year.
- Becton Dickinson cash flow from investing activities for the twelve months ending December 31, 2023 was $-2.326B, a 59.23% decline year-over-year.
- Becton Dickinson annual cash flow from investing activities for 2023 was $-0.716B, a 77.76% decline from 2022.
- Becton Dickinson annual cash flow from investing activities for 2022 was $-3.22B, a 74.72% increase from 2021.
- Becton Dickinson annual cash flow from investing activities for 2021 was $-1.843B, a 54.87% increase from 2020.
Becton Dickinson Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-716 |
| 2022 |
$-3,220 |
| 2021 |
$-1,843 |
| 2020 |
$-1,190 |
| 2019 |
$-741 |
| 2018 |
$-15,733 |
| 2017 |
$-883 |
| 2016 |
$-669 |
| 2015 |
$-8,318 |
| 2014 |
$-948 |
| 2013 |
$-311 |
| 2012 |
$-894 |
| 2011 |
$-1,033 |
| 2010 |
$-694 |
| 2009 |
$-1,067 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$68.385B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
